Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A quick guide outlining which cryptocurrency to buy first, focusing on accessibility, liquidity, and practical use cases for newcomers.
24,236 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Fidelity's FTEC and Vanguard's VGT mirror the same U.S. tech index, but the subtle fee differences and fund mechanics...
Today brought a notable move for fintech investors as fiserv stock topped market headlines. Here’s what sparked the r...
A CFO selling NuScale stock can spark questions about the company’s outlook. This guide breaks down what the move mig...
Momentum can tilt a portfolio toward recent winners. This article explains how two Vanguard ETFs using momentum aim t...
Hudbay's 2025 earnings outlook hinges on copper and zinc markets, mine costs, and capital decisions. This guide break...
Netflix stock climbed today as investors weighed growth momentum and the potential move of a major deal. This article...
Asana's 2026 earnings outlook blends strong ARR growth with improving efficiency. This guide breaks down the key numb...
In late 2025, Berkshire added 8 million shares to a major energy producer, lifting its portfolio weight. This move po...
U.S. consumer prices rose modestly in February, keeping annual inflation at 2.4% with a 0.3% monthly gain. Analysts s...
Start your week with a curated set of monday reads that translate headlines into practical investing moves. This guid...
A trio of XRP ETFs began trading in 2026, offering exposure to XRP without direct coin ownership. This piece reviews ...